KYTRIL
LOE ApproachingNDAORALSOLUTION
Approved
Jun 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYTRIL is an oral solution small-molecule drug approved by Roche in 2001 for solid tumors. The mechanism of action and specific pharmacological class are not documented in available data. This product is indicated for oncology patients requiring oral antiemetic or supportive care therapy.
LOE Approaching
As LOE approaches, commercial teams will focus on lifecycle extension strategies and preparing for generic competition; expect consolidation of marketing support and shift toward specialty/institutional channels.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy
Started Apr 2007
171 enrolled
Post-Operative Nausea and Vomiting
Career Relevance
KYTRIL offers limited career growth potential given its LOE-approaching lifecycle stage and zero linked job openings. Professionals working on this brand should prioritize transition planning or seek roles on growth-stage oncology products within the Roche portfolio.
Brand Manager
Worked on KYTRIL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.